BackVir Biotechnology Overview
Vir Biotechnology Inc

Vir Biotechnology Target Price

See Vir Biotechnology's analyst price targets ($25) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$11.39

Average Target Price

$25.00119.6% upside

3 analysts in the last 4 months

High: $27 | Low: $23

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-06Morgan Stanley$25119.6% upsideOpen
2026-06-11Morgan Stanley$27137.2% upsideOpen
2026-05-08Morgan Stanley$23102% upsideOpen
2026-03-04H.C. WainwrightPatrick Trucchio$2075.7% upsideOpen
2026-02-26Leerink PartnersRoanna Ruiz$2075.7% upsideOpen
2026-02-24Barclays$30163.5% upsideOpen
2026-02-24Evercore ISICory Kasimov$1858.1% upsideOpen
2026-02-24NeedhamJoseph Stringer$1858.1% upsideOpen
2026-02-24Morgan StanleyMichael Ulz$24110.8% upsideOpen
2026-02-24Raymond JamesSean McCutcheon$1966.9% upsideOpen
2026-02-17Barclays$26128.4% upsideOpen
2026-02-04BarclaysEtzer Darout$24110.8% upsideOpen
2025-12-30H.C. WainwrightPatrick Trucchio$1531.8% upsideOpen
2025-07-11Raymond JamesSean McCutcheon$125.4% upsideOpen
2025-01-09Morgan StanleyMichael Ulz$2075.7% upsideOpen
2024-08-02BarclaysGena Wang$28145.9% upsideOpen
2024-06-05Morgan StanleyMichael Ulz$1531.8% upsideOpen
2024-05-21BarclaysGena Wang$27137.2% upsideOpen
2023-02-21Goldman SachsPaul Choi$28.38149.3% upsideOpen
2022-05-06NeedhamJoseph Stringer$35207.4% upsideOpen

Vir Biotechnology (VIR) FAQ

Vir Biotechnology posts a target price of $25. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $25 for VIR means covering analysts, on average, see the stock 119.6% upside of $11.39 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for VIR's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Vir Biotechnology's other metric pages and overview cover the third.

Judging Vir Biotechnology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $25 here, then scan peer and history charts to see if the gap is persistent.